Early Phase II Study on BNCT in Metastatic Malignant Melanoma Using the Boron Carrier BPA (EORTC Protocol 11011)
The aim of the trial is to examine the clinical response of metastatic melanoma following BNCT with BPA.
The trial contains an optional biodistribution sub-study , which is done if operable metastases are removed prior BNCT. BNCT is applied in 2 fractions at the HFR in Petten. In cases of diffuse brain metastases the whole brain is irradiated homogeneously using 5 irradiation beams from different directions. Up to now 4
patients suffering from multiple brain metastases (more than 20) have been included. In all cases we observed a partial response or no change in the irradiated volume. However, none of the patients survived more than 3 months. The pharmacokinetic of the BPA can be predicted very precisely using a two-compartment model.
The treatment can be performed safely.
SAUERWEIN Wolfgang;
MOSS Raymond;
STECHER-RASMUSSEN Finn;
NIEVAART Victor Alexander;
GRABBE Stephan;
HEIMANS Jan;
COLLETTE Laurence;
VAN LOENEN Arie;
BUEHRMANN Sandra;
ROCA Antoaneta;
HOVING Anton;
RASSOW Juergen;
WITTIG Andrea;
2006-11-17
International Society for Neutron Capture Therapy: ISNCT
JRC35042
https://publications.jrc.ec.europa.eu/repository/handle/JRC35042,
Additional supporting files
| File name | Description | File type | |
|---|
